Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines to present zolucatetide desmoid tumor data at ESMO on October 24

Neutral Impact 2 of 5 product/contract Written later

Parabilis Medicines said it plans an oral presentation of updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the ESMO Congress 2026 in Madrid, Spain. The filing describes the update as a change to its guidance, but it gives no financial figures, so the disclosure mainly signals upcoming clinical data for shareholders to watch.

Key points

  • Presentation is scheduled for Saturday, October 24, 2026, in a sarcoma-focused Proffered Paper session.
  • Session begins at 2:45pm CEST (8:45am ET).
  • Data come from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients.
  • The filing was furnished under Item 7.01 (Regulation FD Disclosure) and was signed by CFO Thomas Kotarakos.

The filing

CompanyParabilis Medicines, Inc. (PBLS)
Form8-K, current report
Filed with the SECSep 15, 2026, 4:15 PM ET
Accession number0001193125-26-391952

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.